Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADPTNASDAQ:DYNNASDAQ:ERASNASDAQ:VERA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADPTAdaptive Biotechnologies$9.52+2.3%$8.30$2.99▼$10.28$1.45B1.751.58 million shs1.76 million shsDYNDyne Therapeutics$11.82-3.4%$10.29$6.36▼$47.45$1.34B1.191.63 million shs1.13 million shsERASErasca$1.42-2.4%$1.29$1.01▼$3.45$400.85M1.121.74 million shs4.01 million shsVERAVera Therapeutics$19.02-4.6%$22.10$18.53▼$51.61$1.27B1.28795,677 shs2.15 million shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADPTAdaptive Biotechnologies+1.75%+5.32%+22.34%+12.71%+160.06%DYNDyne Therapeutics+4.08%+2.86%+4.44%-10.07%-60.62%ERASErasca+31.82%+19.83%+1.40%+5.84%-39.83%VERAVera Therapeutics+5.62%+1.53%-16.96%-33.41%-46.31%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADPTAdaptive Biotechnologies3.1976 of 5 stars1.42.00.04.24.22.50.6DYNDyne Therapeutics3.0694 of 5 stars4.51.00.00.02.83.30.0ERASErasca3.7233 of 5 stars4.51.00.00.04.02.51.3VERAVera Therapeutics2.1162 of 5 stars3.61.00.00.03.22.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADPTAdaptive Biotechnologies 2.83Moderate Buy$9.833.29% UpsideDYNDyne Therapeutics 3.07Buy$47.15298.93% UpsideERASErasca 3.00Buy$4.57223.07% UpsideVERAVera Therapeutics 3.10Buy$63.33232.98% UpsideCurrent Analyst Ratings BreakdownLatest ERAS, ADPT, DYN, and VERA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2025DYNDyne TherapeuticsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$46.005/14/2025ERASErascaGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$3.005/9/2025DYNDyne TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$46.00 ➝ $38.005/9/2025DYNDyne TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.00 ➝ $50.005/7/2025VERAVera TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$34.00 ➝ $26.005/7/2025VERAVera TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$107.00 ➝ $100.005/6/2025ADPTAdaptive BiotechnologiesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$11.00 ➝ $13.005/5/2025ADPTAdaptive BiotechnologiesMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$7.00 ➝ $9.005/5/2025VERAVera TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$75.005/2/2025ADPTAdaptive BiotechnologiesThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$9.00 ➝ $10.004/30/2025ERASErascaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.00(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADPTAdaptive Biotechnologies$189.53M7.63N/AN/A$1.37 per share6.95DYNDyne TherapeuticsN/AN/AN/AN/A$1.49 per shareN/AERASErascaN/AN/AN/AN/A$2.10 per shareN/AVERAVera TherapeuticsN/AN/AN/AN/A$1.94 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADPTAdaptive Biotechnologies-$159.49M-$0.96N/AN/AN/A-89.12%-64.65%-26.45%8/7/2025 (Estimated)DYNDyne Therapeutics-$235.94M-$3.59N/AN/AN/AN/A-57.46%-51.62%8/11/2025 (Estimated)ERASErasca-$125.04M-$0.62N/AN/AN/AN/A-42.26%-34.97%8/11/2025 (Estimated)VERAVera Therapeutics-$95.99M-$3.00N/AN/AN/AN/A-50.13%-39.50%8/14/2025 (Estimated)Latest ERAS, ADPT, DYN, and VERA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025ERASErasca-$0.12-$0.11+$0.01-$0.11N/AN/A5/8/2025Q1 2025DYNDyne Therapeutics-$0.88-$1.05-$0.17-$1.05N/AN/A5/8/2025Q1 2025VERAVera Therapeutics-$0.75-$0.81-$0.06-$0.81N/AN/A5/1/2025Q1 2025ADPTAdaptive Biotechnologies-$0.28-$0.20+$0.08-$0.20$42.13 million$52.44 million3/20/2025Q4 2024ERASErasca-$0.12-$0.11+$0.01-$0.11N/AN/A3/4/2025Q4 2024DYNDyne Therapeutics-$0.92-$0.88+$0.04-$0.88N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADPTAdaptive BiotechnologiesN/AN/AN/AN/AN/ADYNDyne TherapeuticsN/AN/AN/AN/AN/AERASErascaN/AN/AN/AN/AN/AVERAVera TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADPTAdaptive BiotechnologiesN/A2.892.81DYNDyne TherapeuticsN/A17.0217.02ERASErascaN/A11.0011.00VERAVera Therapeutics0.1713.7613.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADPTAdaptive Biotechnologies99.17%DYNDyne Therapeutics96.68%ERASErasca67.78%VERAVera Therapeutics99.21%Insider OwnershipCompanyInsider OwnershipADPTAdaptive Biotechnologies6.40%DYNDyne Therapeutics14.14%ERASErasca14.40%VERAVera Therapeutics16.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADPTAdaptive Biotechnologies790151.92 million138.43 millionOptionableDYNDyne Therapeutics100113.67 million80.63 millionOptionableERASErasca120283.29 million221.94 millionOptionableVERAVera Therapeutics4063.77 million49.58 millionOptionableERAS, ADPT, DYN, and VERA HeadlinesRecent News About These CompaniesVera Therapeutics (NASDAQ:VERA) Stock Price Up 5.7% - Time to Buy?May 30 at 2:08 PM | marketbeat.comVera Therapeutics, Inc. (NASDAQ:VERA) Receives $63.33 Consensus PT from AnalystsMay 29 at 1:43 AM | americanbankingnews.comVera Therapeutics, Inc. (NASDAQ:VERA) Given Average Rating of "Buy" by AnalystsMay 27 at 1:17 AM | marketbeat.comCantor Fitzgerald maintains Vera Therapeutics at OverweightMay 26, 2025 | uk.investing.comBNP Paribas Financial Markets Purchases Shares of 24,374 Vera Therapeutics, Inc. (NASDAQ:VERA)May 23, 2025 | marketbeat.comWoodline Partners LP Acquires 201,573 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)May 22, 2025 | marketbeat.comMarker Therapeutics CEO Dr. Juan Vera to Join Expert Panel Discussing CD19 CAR-T Therapy at Upcoming WebcastMay 21, 2025 | nasdaq.comVestal Point Capital LP Acquires Shares of 1,075,000 Vera Therapeutics, Inc. (NASDAQ:VERA)May 21, 2025 | marketbeat.comThornburg Investment Management Inc. Acquires 28,124 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)May 21, 2025 | marketbeat.comVera Therapeutics, Inc. (NASDAQ:VERA) Shares Acquired by Point72 Asset Management L.P.May 21, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Decreases Stock Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA)May 21, 2025 | marketbeat.comMPM Bioimpact LLC Acquires New Position in Vera Therapeutics, Inc. (NASDAQ:VERA)May 16, 2025 | marketbeat.comVera Therapeutics, Inc. (NASDAQ:VERA) Shares Acquired by Paradigm Biocapital Advisors LPMay 16, 2025 | marketbeat.comVera Therapeutics, Inc. (NASDAQ:VERA) Shares Purchased by Nicholas Investment Partners LPMay 16, 2025 | marketbeat.comEquities Analysts Offer Predictions for VERA FY2025 EarningsMay 16, 2025 | marketbeat.comVera Therapeutics, Inc. (NASDAQ:VERA) Holdings Raised by Deutsche Bank AGMay 16, 2025 | marketbeat.comNorthern Trust Corp Has $19.24 Million Stock Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA)May 16, 2025 | marketbeat.comVera Therapeutics: Huge Catalyst Upcoming For Kidney Disease DrugMay 15, 2025 | seekingalpha.comVera Therapeutics, Inc. (NASDAQ:VERA) Shares Purchased by Orbimed Advisors LLCMay 15, 2025 | marketbeat.comVera Therapeutics, Inc. (NASDAQ:VERA) Stock Position Boosted by Integral Health Asset Management LLCMay 14, 2025 | marketbeat.comCubist Systematic Strategies LLC Cuts Stock Position in Vera Therapeutics, Inc. (NASDAQ:VERA)May 14, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsNavitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookBy Leo Miller | May 27, 2025View Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookAfter Earnings Beats, These 3 Stocks Are on Analysts’ RadarsBy Leo Miller | May 20, 2025View After Earnings Beats, These 3 Stocks Are on Analysts’ RadarsStrategists Say Hold: Stocks May Beat the 'Sell in May' TrendBy Jeffrey Neal Johnson | May 9, 2025View Strategists Say Hold: Stocks May Beat the 'Sell in May' TrendWingstop Stock Jumps on Q1 Beat, Expansion OutlookBy Jeffrey Neal Johnson | May 4, 2025View Wingstop Stock Jumps on Q1 Beat, Expansion OutlookERAS, ADPT, DYN, and VERA Company DescriptionsAdaptive Biotechnologies NASDAQ:ADPT$9.52 +0.21 (+2.26%) Closing price 04:00 PM EasternExtended Trading$9.64 +0.12 (+1.21%) As of 07:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.Dyne Therapeutics NASDAQ:DYN$11.82 -0.42 (-3.43%) Closing price 04:00 PM EasternExtended Trading$11.96 +0.15 (+1.23%) As of 04:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.Erasca NASDAQ:ERAS$1.42 -0.04 (-2.41%) Closing price 04:00 PM EasternExtended Trading$1.41 -0.01 (-0.42%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.Vera Therapeutics NASDAQ:VERA$19.02 -0.91 (-4.57%) Closing price 04:00 PM EasternExtended Trading$19.05 +0.03 (+0.16%) As of 06:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell Ackman Takes a Swing at Amazon — Should You? Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Intel’s Turnaround May Be the Best Bet No One’s Watching Nike’s Amazon Expansion Could Signal a Turnaround in 2025 ASML Stock Might Be the Safest Chip Play at This Price Archer Aviation Stock Steadies After Short-Seller Report e.l.f. Beauty Sees Record Surge After Earnings, Rhode Deal Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
